PE20000467A1 - Derivado de indol util como inhibidor de serotonina - Google Patents

Derivado de indol util como inhibidor de serotonina

Info

Publication number
PE20000467A1
PE20000467A1 PE1999000381A PE00038199A PE20000467A1 PE 20000467 A1 PE20000467 A1 PE 20000467A1 PE 1999000381 A PE1999000381 A PE 1999000381A PE 00038199 A PE00038199 A PE 00038199A PE 20000467 A1 PE20000467 A1 PE 20000467A1
Authority
PE
Peru
Prior art keywords
alkyl
indole derivative
derivative useful
serotonin inhibitor
alcoxy
Prior art date
Application number
PE1999000381A
Other languages
English (en)
Inventor
Peter Thaddeus Gallagher
Martin Victor Miles
Colin William Smith
John Fairhurst
William Martin Owton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20000467A1 publication Critical patent/PE20000467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 1-6; m ES 1-2; p ES 1-2; R1 Y R2 SON H, ALQUILO C1-C4, ALCOXI C1-C4, OH-ALQUILO C1-C4, HALO, FENILO OPCIONALMENTE SUSTITUIDO, FENIL-ALQUILO C1-C4, ENTRE OTROS; O R1 Y R2 FORMAN UN CICLOALQUILO C3-C6, >C=O, C=NOR`; R' ES H, ALQUILO C1-C4; R3, R4 Y R5 SON H, HALO, NITRO, ALQUILO C1-C4, ALCOXI C1-C4, CO-ALQUILO C1-C4, R'R''N-SO2-, -COOR', -CONR'R'', -NR'R'', ENTRE OTROS; R' Y R'' SON H, ALQUILO C1-C4; R6 Y R7 SON H, ALQUILO C1-C4; X ES O, S; EL FLUOR ESTA UNIDO EN LAS POSICIONES 6 o 7. EL COMPUESTO I TIENE AFINIDAD SELECTIVA PARA LOS RECEPTORES DE 5HT SIENDO UN MODULADOR SEROTONERGICO UTIL PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL
PE1999000381A 1998-05-13 1999-05-10 Derivado de indol util como inhibidor de serotonina PE20000467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810886.3A GB9810886D0 (en) 1998-05-13 1998-05-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
PE20000467A1 true PE20000467A1 (es) 2000-06-05

Family

ID=10832426

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000381A PE20000467A1 (es) 1998-05-13 1999-05-10 Derivado de indol util como inhibidor de serotonina

Country Status (11)

Country Link
US (1) US6166040A (es)
EP (1) EP0963983A1 (es)
JP (1) JP2002514642A (es)
AR (1) AR018859A1 (es)
AU (1) AU3838499A (es)
CA (1) CA2330796A1 (es)
CO (1) CO5031250A1 (es)
GB (1) GB9810886D0 (es)
PE (1) PE20000467A1 (es)
SV (1) SV1999000059A (es)
WO (1) WO1999058525A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825413D0 (en) 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
GB2362381A (en) * 2000-05-18 2001-11-21 Lilly Co Eli Pharmaceutically active indolyl-piperidines
US6844338B2 (en) 2000-05-18 2005-01-18 Eli Lilly And Company Piperidyindoles as serotonin receptor ligands
DK1294710T3 (da) * 2000-06-14 2005-10-03 Lundbeck & Co As H Indolderivater, der er egnede til behandlingen af CNS-lidelser
AR028685A1 (es) * 2000-06-14 2003-05-21 Lundbeck & Co As H Derivados de indol
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds
DK1392697T3 (da) * 2001-03-14 2005-02-14 Wyeth Corp Antidepressive azaheterocyclylmethylderivater af 2,3-dihydro-1,4-dioxino[2.3-f]quinolin
HUP0400343A2 (hu) 2001-03-29 2004-09-28 Bristol-Myers Squibb Co. Ciklopropil-indol-származékok mint szelektív szerotonin-újrafelvétel inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US6861434B2 (en) * 2001-04-26 2005-03-01 Wyeth Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
US6555560B2 (en) * 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
US6906206B2 (en) 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
CN100352820C (zh) * 2002-09-12 2007-12-05 惠氏公司 抗抑郁的杂环稠合的苯并二噁烷的氮杂环甲基衍生物
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
NZ553202A (en) 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
CN101155587A (zh) * 2004-11-29 2008-04-02 弗特克斯药品有限公司 毒蕈碱受体调节剂
CA2634456A1 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ570497A (en) * 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
EP1988892A2 (en) * 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007269863A1 (en) * 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101553231A (zh) * 2006-08-15 2009-10-07 弗特克斯药品有限公司 毒蕈碱受体调节剂
CA2660974A1 (en) * 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2009045519A1 (en) * 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981881A (en) * 1975-08-14 1976-09-21 E. R. Squibb & Sons, Inc. 2-[(4-Phenyl-tetrahydropyridinyl)alkyl]-1H-isoindole-1,3(2H)-diones
JP2860688B2 (ja) * 1990-03-14 1999-02-24 第一製薬株式会社 インドール誘導体
FR2675801A1 (fr) * 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, leur preparation et les medicaments les contenant.
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
TW421649B (en) * 1995-01-31 2001-02-11 Janssen Pharmaceutica Nv 4-(1H-indol-1yl)-1-piperidinyl derivatives
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives

Also Published As

Publication number Publication date
WO1999058525A1 (en) 1999-11-18
CA2330796A1 (en) 1999-11-18
SV1999000059A (es) 2000-07-04
JP2002514642A (ja) 2002-05-21
US6166040A (en) 2000-12-26
CO5031250A1 (es) 2001-04-27
GB9810886D0 (en) 1998-07-22
AU3838499A (en) 1999-11-29
AR018859A1 (es) 2001-12-12
EP0963983A1 (en) 1999-12-15

Similar Documents

Publication Publication Date Title
PE20000467A1 (es) Derivado de indol util como inhibidor de serotonina
CO4440628A1 (es) Derivados de pirimidina condensados con un anillo heteroci- clico
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
PE20030292A1 (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa
PE20020692A1 (es) Compuestos derivados de benzotiofeno y su procedimiento de obtencion
CO5180649A1 (es) Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
ES2064973T3 (es) Nuevos derivados de indol.
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
CO5261632A1 (es) Inhibidores de la recaptacion de monoamidas para el tratamiento del snc
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
FI982572A (fi) Aryylisubstituoituja syklisiä amiineja selektiivisinä dopamiini-D3-ligandeina
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
UY25873A1 (es) Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos
ECSP066520A (es) Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso
PE20010575A1 (es) Derivados de indol y su uso como ligandos del receptor 5ht2
PE10997A1 (es) NUEVOS DERIVADOS DE [3-(4-FENILPIPERACIN-1-i1)PROPILAMINO]-PIRIDINA, PIRIMIDINA Y BENCENO COMO ANTAGONISTAS DE a1-ADRENOCEPTORES, SUS EMPLEOS COMO AGENTES TERAPEUTICOS Y LOS METODOS PARA SU PREPARACION
AR015036A1 (es) Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
PE20000055A1 (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
PE20080126A1 (es) Metodos para tratar trastornos cognitivos y otros afines
AR010306A1 (es) Compuesto derivado de 4-aril-3-hidroxiquinolin-2-ona, composicion farmaceutica que lo comprende y su uso.
PE20010481A1 (es) Derivados de la octahidro-1h-pirido[1,2-a]pirazina 2,7-sustituida como ligandos para receptores de la serotonina

Legal Events

Date Code Title Description
FC Refusal